Hubei Jianxiang Bioscience: difference between revisions
Diff·revision 9 → 10·15:46, 18 Jul 2025
Difference between revision 9 and revision 10 of Hubei Jianxiang Bioscience. 9 lines changed; the page grew by 618 bytes.
| Revision 9 — 19:35, 29 Jun 2025 BatchNumberBede (talk) ce 7,008 bytes +899 | Revision 10 — 15:46, 18 Jul 2025 GlossaryGleb (talk) expand §Reception 7,626 bytes +618 | ||
|---|---|---|---|
| 52 | Submitted reports on HJ material to July 2026 are concentrated on the incretin analogues, with reported [[Area percent purity|area percent]] figures clustering in the high nineties and, where a water figure accompanied them, purchaser-computed [[Peptide content|peptide content]] in the low-to-mid eighties by mass.{{r|reports,usp1503}} | 52 | Submitted reports on HJ material to July 2026 are concentrated on the incretin analogues, with reported [[Area percent purity|area percent]] figures clustering in the high nineties and, where a water figure accompanied them, purchaser-computed [[Peptide content|peptide content]] in the low-to-mid eighties by mass.{{r|reports,usp1503}} |
| 53 | 53 | ||
| + | 54 | A [[Peptide content|peptide content]] in the low eighties alongside a purity of 99% is the arithmetically expected pairing for a lyophilised peptide carrying a trifluoroacetate counterion and several per cent water, not an inconsistency. It is spelled out here because readers seeing the two figures on one certificate frequently take the difference for an error, and because HJ's certificates report both, which is what makes the arithmetic checkable at all.{{r|usp1503}} | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |
| ⋮ | ⋮ | ||
| 60 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 62 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| 61 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 63 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 64 | ||
| + | 65 | == See also == | |
| + | 66 | * [[Certificate of analysis]] | |
| + | 67 | * [[Third-party testing]] | |
| + | 68 | * [[Area percent purity]] | |
| + | 69 | * [[Peptide content]] | |
| + | 70 | * [[Research use only]] | |
| 62 | 71 | ||
| 63 | {{DEFAULTSORT:Hubei Jianxiang Bioscience}} | 72 | {{DEFAULTSORT:Hubei Jianxiang Bioscience}} |